Extended Data Fig. 6: Ad-LacZ/FlexON activates pulmonary Ccl19-expressing immune-stimulatory FSCs.
a, Averaged expression of cluster specific marker genes for pulmonary FSC clusters in merged naive and Ad-LacZ/FlexON-immunized Ccl19-EYFP mice. b, Heatmaps displaying indicated genes across all Lumhigh and Il33high FSCs in EYFP+ FSCs from Ad-LacZ/FlexON-immunized or naive mice. c, Prediction of differentiation dynamics based on RNA velocity analysis of EYFP+ FSCs constructed based on recent changes in the transcriptional rate of a gene to predict the future state of individual cells. d, Representative flow cytometric analysis of Sca-1+CD34+ cell populations within EYFP+ cells. e, Frequency Sca-1+ CD34+ cell within EYFP+ cells. f, Quantitative real-time PCR analysis of Il33 expression in pulmonary EYFP+ FSCs. g, Quantitative real-time PCR analysis of Il33 expression in EYFP+ pulmonary FSC populations. h, Quantitative real-time PCR analysis of LacZ mRNA copy numbers per 1,000 cells in the indicated EYFP+ pulmonary FSC populations. i, Reconstruction of IL-33 staining in lung EYFP+ cells of Ccl19-EYFP mice at indicated time points after Ad-LacZ/FlexON immunization, based on images shown in Fig. 5j. Scale bar equals 30 μm. Dots represent individual mice and bar graphs indicate mean ±s.e.m. Pooled data from two independent experiments with n = 8 naive and 9 AdLacZFlexON immunized [(e)]; n = 5 [(f)], n = 6 [(h)] mice; one experiment n = 6 mice [(g)]. Representative data from n = 4 mice per group (i). Statistical analysis was performed using unpaired two-tailored Student’s t test [(e)], Mann Whitney [(f), (g)], one-way ANOVA with Turkey`s multiple comparison test [(h)] with *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Exact P values are provided in the Source Data.
